Efficacy and safety of thalidomide in preventing oral mucositis in patients with nasopharyngeal carcinoma undergoing concurrent chemoradiotherapy: A multicenter, open-label, randomized controlled trial

Leifeng Liang, Zhibing Liu, Haisheng Zhu, Hongqian Wang, Yan Wei, Xuejian Ning, Zhiling Shi, Liujun Jiang, Zhan Lin, Haolin Yan, Rensheng Wang, Kai Hu, Leifeng Liang, Zhibing Liu, Haisheng Zhu, Hongqian Wang, Yan Wei, Xuejian Ning, Zhiling Shi, Liujun Jiang, Zhan Lin, Haolin Yan, Rensheng Wang, Kai Hu

Abstract

Background: This multicenter clinical trial was designed to evaluate the efficacy and safety of thalidomide (THD) in preventing oral mucositis (OM) in patients with nasopharyngeal carcinoma (NPC) undergoing concurrent chemoradiotherapy (CCRT).

Methods: Patients with locally advanced NPC were randomly assigned to either a THD group or a control group. All 160 patients received radical intensity-modulated radiotherapy plus cisplatin-based concurrent chemotherapy and basic oral hygiene guidance. Patients in the THD group received additional THD at the beginning of CCRT. The primary end points were the latency period and the incidence of OM. The secondary end points were mouth and throat soreness (MTS), weight loss, short-term efficacy, and adverse events.

Results: The median latency period of OM was 30 and 14 days in the THD and control groups, respectively (hazard ratio, 0.32; 95% confidence interval, 0.23-0.35; P < .0001). The incidence of OM and severe OM (World Health Organization grade 3 or higher) was significantly lower in the THD group than the control group (87.5% vs 97.5% [P = .016] and 27.5% vs 46.3% [P = .014], respectively). THD treatment also remarkably reduced the intensity of MTS and the degree of weight loss. In comparison with the control group, the incidence of nausea, vomiting, and insomnia was significantly decreased, whereas the incidence of dizziness and constipation was obviously increased in the THD group. The objective response rates 3 months after CCRT were similar between the groups.

Conclusions: THD prolonged the latency period, reduced the incidence of OM, and did not affect the short-term efficacy of CCRT in patients with NPC.

Lay summary: Oral mucositis is the most common complication of nasopharyngeal carcinoma during chemoradiotherapy; it decreases the patient's quality of life, and ideal mucosal protective agents are lacking. A few basic research and preclinical studies have shown that thalidomide may be an approach to ameliorating oral mucositis. The results of the current study confirm that thalidomide has a protective effect against oral mucositis in patients who have received chemoradiotherapy for nasopharyngeal carcinoma.

Keywords: concurrent chemoradiotherapy; efficacy; nasopharyngeal carcinoma; oral mucositis; safety; thalidomide.

© 2021 American Cancer Society.

References

    1. Chen YP, Chan ATC, Le QT, Blanchard P, Sun Y, Ma J. Nasopharyngeal carcinoma. Lancet. 2019;394:64-80.
    1. Wei KR, Zheng RS, Zhang SW, Liang ZH, Li ZM, Chen WQ. Nasopharyngeal carcinoma incidence and mortality in China, 2013. Chin J Cancer. 2017;36:90.
    1. Al-Sarraf M, LeBlanc M, Giri PG, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol. 1998;16:1310-1317.
    1. Lee AWM, Lau WH, Tung SY, et al. Preliminary results of a randomized study on therapeutic gain by concurrent chemotherapy for regionally-advanced nasopharyngeal carcinoma: NPC-9901 trial by the Hong Kong Nasopharyngeal Cancer Study Group. J Clin Oncol. 2005;23:6966-6975.
    1. Jiang CL, Wang H, Xia CF, et al. A randomized, double-blind, placebo-controlled trial of probiotics to reduce the severity of oral mucositis induced by chemoradiotherapy for patients with nasopharyngeal carcinoma. Cancer. 2019;125:1081-1090.
    1. Kostler WJ, Hejna M, Wenzel C, Zielinski CC. Oral mucositis complicating chemotherapy and/or radiotherapy: options for prevention and treatment. CA Cancer J Clin. 2001;51:290-315.
    1. Li PJ, Li KX, Jin T, et al. Predictive model and precaution for oral mucositis during chemo-radiotherapy in nasopharyngeal carcinoma patients. Front Oncol. 2020;10:596822.
    1. Elad S, Cheng KKF, Lalla RV, et al. MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer. 2020;126:4423-4431.
    1. Migliorati C, Hewson I, Lalla RV, et al. Systematic review of laser and other light therapy for the management of oral mucositis in cancer patients. Support Care Cancer. 2013;21:333-341.
    1. Sonis ST, Hashemi S, Epstein JB, Nair RG, Raber-Durlacher JE. Could the biological robustness of low level laser therapy (photobiomodulation) impact its use in the management of mucositis in head and neck cancer patients. Oral Oncol. 2016;54:7-14.
    1. Zadik Y, Arany PR, Fregnani ER, et al. Systematic review of photobiomodulation for the management of oral mucositis in cancer patients and clinical practice guidelines. Support Care Cancer. 2019;27:3969-3983.
    1. Franks ME, Macpherson GR, Figg WD. Thalidomide. Lancet. 2004;363:1802-1811.
    1. Frings K, Gruber S, Kuess P, Kleiter M, Dorr W. Modulation of radiation-induced oral mucositis by thalidomide: preclinical studies. Strahlenther Onkol. 2016;192:561-568.
    1. Lima V, Brito GAC, Cunha FQ, et al. Effects of the tumour necrosis factor-alpha inhibitors pentoxifylline and thalidomide in short-term experimental oral mucositis in hamsters. Eur J Oral Sci. 2005;113:210-217.
    1. Zeng QX, Shi XK, Yang J, et al. The efficacy and safety of thalidomide on the recurrence interval of continuous recurrent aphthous ulceration: a randomized controlled clinical trial. J Oral Pathol Med. 2020;49:357-364.
    1. Ramirez-Amador VA, Esquivel-Pedraza L, Ponce-de-Leon S, et al. Thalidomide as therapy for human immunodeficiency virus-related oral ulcers: a double-blind placebo-controlled clinical trial. Clin Infect Dis. 1999;28:892-894.
    1. Hamuryudan V, Mat C, Saip S, et al. Thalidomide in the treatment of the mucocutaneous lesions of the Behcet syndrome. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1998;128:443-450.
    1. Liang LF, Zhong JH, Yan HL, Gan M, Lin Z, Zhu HS. The efficacy of thalidomide on preventing and treating radiation-induced oral mucositis in nasopharyngeal carcinoma. Chin J Clin Oncol. 2017;44:1189-1193.
    1. Yen SH, Wang LW, Lin YH, Jen YM, Chung YL. Phenylbutyrate mouthwash mitigates oral mucositis during radiotherapy or chemoradiotherapy in patients with head-and-neck cancer. Int J Radiat Oncol. 2012;82:1463-1470.
    1. Zheng BM, Zhu XD, Liu MZ, et al. Randomized, double-blind, placebo-controlled trial of Shuanghua Baihe tablets to prevent oral mucositis in patients with nasopharyngeal cancer undergoing chemoradiation therapy. Int J Radiat Oncol. 2018;100:418-426.
    1. Peterson DE, Boers-Doets CB, Bensadoun RJ, Herrstedt J, Comm EG. Management of oral and gastrointestinal mucosal injury: ESMO clinical practice guidelines for diagnosis, treatment, and follow-up. Ann Oncol. 2015;26:V139-V151.
    1. Lv X, Cao X, Xia WX, et al. Induction chemotherapy with lobaplatin and fluorouracil versus cisplatin and fluorouracil followed by chemoradiotherapy in patients with stage III-IVB nasopharyngeal carcinoma: an open-label, non-inferiority, randomised, controlled, phase 3 trial. Lancet Oncol. 2021;22:716-726.
    1. Zhang Y, Chen L, Hu GQ, et al. Gemcitabine and cisplatin induction chemotherapy in nasopharyngeal carcinoma. N Engl J Med. 2019;381:1124-1135.
    1. Hensley ML, Hagerty KL, Kewalramani T, et al. American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants. J Clin Oncol. 2009;27:127-145.
    1. Nicolatou-Galitis O, Sarri T, Bowen J, et al. Systematic review of amifostine for the management of oral mucositis in cancer patients. Support Care Cancer. 2013;21:357-364.
    1. Epstein JB, Silverman S, Paggiarino DA, et al. Benzydamine HCl for prophylaxis of radiation-induced oral mucositis-results from a multicenter, randomized, double-blind, placebo-controlled clinical trial. Cancer. 2001;92:875-885.
    1. Kazemian A, Kamian S, Aghili M, Hashemi FA, Haddad P. Benzydamine for prophylaxis of radiation-induced oral mucositis in head and neck cancers: a double-blind placebo-controlled randomized clinical trial. Eur J Cancer Care. 2009;18:174-178.
    1. Logan RM, Al-Azri AR, Bossi P, et al. Systematic review of growth factors and cytokines for the management of oral mucositis in cancer patients and clinical practice guidelines. Support Care Cancer. 2020;28:2485-2498.
    1. Le QT, Kim HE, Schneider CJ, et al. Palifermin reduces severe mucositis in definitive chemoradiotherapy of locally advanced head and neck cancer: a randomized, placebo-controlled study. J Clin Oncol. 2011;29:2808-2814.
    1. Yarom N, Hovan A, Bossi P, et al. Systematic review of natural and miscellaneous agents, for the management of oral mucositis in cancer patients and clinical practice guidelines-part 2: honey, herbal compounds, saliva stimulants, probiotics, and miscellaneous agents. Support Care Cancer. 2020;28:2457-2472.
    1. Sonis ST. The pathobiology of mucositis. Nat Rev Cancer. 2004;4:277-284.
    1. Bowen J, Al-Dasooqi N, Bossi P, et al. The pathogenesis of mucositis: updated perspectives and emerging targets. Support Care Cancer. 2019;27:4023-4033.
    1. Keifer JA, Guttridge DC, Ashburner BP, Baldwin AS. Inhibition of NF-κB activity by thalidomide through suppression of IκB kinase activity. J Biol Chem. 2001;276:22382-22387.
    1. Rance E, Tanner JE, Alfieri C. Inhibition of IκB kinase by thalidomide increases hepatitis C virus RNA replication. J Viral Hepat. 2012;19:E73-E80.
    1. Moreau P, Attal M, Hulin C, et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. Lancet. 2019;394:29-38.
    1. Yu JP, Sun SP, Sun ZQ, et al. Clinical trial of thalidomide combined with radiotherapy in patients with esophageal cancer. World J Gastroenterol. 2014;20:5098-5103.
    1. Shi SB, Wang M, Niu ZX, Tang XY, Liu QY. Phase II trial of capecitabine combined with thalidomide in second-line treatment of advanced pancreatic cancer. Pancreatology. 2012;12:475-479.
    1. Chen L, Qiu XX, Wang RX, Xie XH. The efficacy and safety of docetaxel plus thalidomide vs. docetaxel alone in patients with androgen-independent prostate cancer: a systematic review. Sci Rep. 2014;4:4818.
    1. Eleutherakis-Papaiakovou V, Bamias A, Dimopoulos MA. Thalidomide in cancer medicine. Ann Oncol. 2004;15:1151-1160.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir